



You are cordially invited to attend a  
**LIVE WEBINAR speaker program for:**  
**SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted)**

Day	Date	Program	Speaker	Time			
				ET	CT	MT	PT
May							
Wed	11	Implementing SHINGRIX in Patients 50 years of age and older	Stephen Tying, MD	1:15 PM	12:15 PM	11:15 AM	10:15 AM
Thu	19	Implementing SHINGRIX in Patients 50 years of age and older	Sean Leng, MD, PhD	12:15 PM	11:15 AM	10:15 AM	9:15 AM
Wed	25	Implementing SHINGRIX in IC Patients 18 years of age and older	Carrie Koenigsfeld, PharmD, FAPhA	3:15 PM	2:15 PM	1:15 PM	12:15 PM

**Please register at [SHINGRIXHCPSignUp.com](https://SHINGRIXHCPSignUp.com) to confirm your participation.**

To join any of the webinar offerings, select the desired date(s), complete the form, and click the Submit button on the registration page.

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

- in adults aged 50 years and older.
- in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

#### IMPORTANT SAFETY INFORMATION

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)
- Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see accompanying full [Prescribing Information](#).

#### Please Read:

In order to be in compliance with the PhRMA Code on Interactions with Healthcare Professionals and other regulations and policies, attendance is limited to healthcare professionals. Accordingly, attendance by guests or spouses is not permitted.

This is a promotional program and no CME credits are offered. This educational program may include the provision of a modest meal. GSK does not intend to offer such a meal to healthcare professionals (HCPs) whose institutions prohibit such hospitality, nor does GSK offer a meal where federal or state laws limit an HCP's ability to accept such a meal. Accordingly, please consult your legal or ethics advisor regarding any applicable limitation before attending this educational program.

Please note that GSK is required to report the value of a provided meal pursuant to applicable federal and/or state laws.

This invitation is nontransferable.

Promotional program sponsored by GSK.

Trademarks are owned by or licensed to the GSK group of companies.



©2022 GSK or licensor.  
SGXLBND210027 January 2022  
Produced in USA.